2 not yet recruiting, 1 completed. 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow SDK Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. ATRA, Arsenic Trioxide (ATO), Gemcitabine - Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Daniel Breadner | 10 | 2026-02-15 | 2026-01-16 |
| A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA) - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Not yet recruiting | SDK Therapeutics, Inc. | 120 | 2026-01-01 | 2025-12-29 |
| Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state - Acute Promyelocytic Leukemia (APL) | Phase 1 | Completed | SDK Therapeutics, Inc. | 12 | 2025-03-11 | 2025-11-18 |
Leukemia, Promyelocytic, Acute (2) · Leukemia (1) · Neoplasm Metastasis (1)
Arsenic Trioxide (3) · Tretinoin (2) · 130-nm albumin-bound paclitaxel (1) · Gemcitabine (1) · tislelizumab (1)
Canada (1) · Hong Kong (1)
Daniel Breadner (1)
2025 (1)